U.S. Patents

In accordance with Section 287(a) of Title 35 of the United States Code, the following list identifies Sanofi’s rights in U.S. patents associated with the listed products. This list may be a subset of Sanofi’s rights in U.S. patents directed to the relevant product. The absence of a product or a U.S. patent number from this list does not constitute a waiver of Sanofi’s patent, trademark, or other intellectual property rights.

Prescription ProductsU.S. Patent No.
Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
U.S. Patent No. 7,404,956U.S. Patent No. 10,058,480U.S. Patent No. 10,588,949U.S. Patent No. 10,849,823
ALTUVIIIO®[Antihemophilic Factor (Recombinant),Fc-VWF-XTEN Fusion Protein-ehtl]
U.S. Patent No. 8,673,860U.S. Patent No. 9,371,369U.S. Patent No. 10,138,291U.S. Patent No. 10,421,798U.S. Patent No. 11,192,936U.S. Patent No. 11,370,827
Cablivi® (caplacizumab-yhdp)
U.S. Patent No. 7,807,162U.S. Patent No. 8,372,398U.S. Patent No. 10,035,862
Caprelsa® (vandetanib) Tablets
U.S. Patent No. 8,067,427
Cerdelga® (eliglustat) capsules
U.S. Patent No. 7,196,205U.S. Patent No. 11,458,119
Dupixent® (dupilumab) Injectionis a product in collaboration with Regeneron.
U.S. Patent No. 7,608,693U.S. Patent No. 8,735,095U.S. Patent No. 8,945,559U.S. Patent No. 9,238,692U.S. Patent No. 10,435,473U.S. Patent No. 11,059,896U.S. Patent No. 11,926,670
Eloctate® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
U.S. Patent No. 7,404,956U.S. Patent No. 9,623,088U.S. Patent No. 10,058,480U.S. Patent No. 10,849,823
Enjaymo® (sutimlimab-jome) injection, for intravenous use
U.S. Patent No. 8,877,197U.S. Patent No. 8,945,562U.S. Patent No. 10,450,382
Jevtana® (cabazitaxel) Injection
U.S. Patent No. 7,241,907
Kevzara® (sarilumab) Injectionis a product in collaboration with Regeneron.
U.S. Patent No. 7,582,298U.S. Patent No. 8,183,014U.S. Patent No. 10,072,086U.S. Patent No. 11,098,127U.S. Patent No. 12,077,593
Nexviazyme® (avalglucosidase alfa-ngpt)
U.S. Patent No. 8,759,501
Rezurock® (belumosudil) tablets
U.S. Patent No. 8,357,693
Sarclisa® (isatuximab-irfc)
U.S. Patent No. 8,153,765
Soliqua® 100/33 (insulin glargine and lixisenatide)injection 100 Units/mL and 33 mcg/mL
U.S. Patent No. RE45,313U.S. Patent No. 9,526,764U.S. Patent No. 9,707,176U.S. Patent No. 9,717,852U.S. Patent No. 10,029,011U.S. Patent No. 10,117,909
Toujeo® (insulin glargine injection) 300 Units/mL
U.S. Patent No. 9,345,750U.S. Patent No. 10,369,291U.S. Patent No. 11,213,628U.S. Patent No. 11,376,365U.S. Patent No. 11,400,218
Zaltrap® (ziv-aflibercept) Injection for Intravenous Infusion
U.S. Patent No. 8,110,546U.S. Patent No. 8,710,004
Vaccines ProductsU.S. Patent No.
MenQuadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine)
U.S. Patent No. 11,147,866

Please See Full Prescribing Information, including Boxed Warning, for Caprelsa, Jevtana, Kevzara,  Nexviazyme, Zaltrap.

MAT-US-2208923-v6.0-10/2024